Coming up with an idea is easy. Developing the idea into a product and full-fledged company is a difficult but ultimately rewarding process for ophthalmologists looking to branch out as entrepreneurs.Every product or company starts out as a singular initial idea that someone chooses to either pursue or ignore, Gary N. Wörtz, MD, founder of Omega Ophthalmics, said
St. Jude Children’s Research Hospital researchers report a topotecan-based chemotherapy regimen should be considered front-line therapy for patients with advanced bilateral retinoblastoma; an eye…
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for Lucentis® (ranibizumab injection) for the treatment of myopic choroidal neovascularization (mCNV), a complication of severe near-sightedness that can lead to blindness. The sBLA is based on results from the Phase III RADIA
Copay assistance, a seeming resolution to the drug pricing dilemma, is actually the problem, according to a commentary published in Annals of Internal Medicine.The 600% price hike of Mylan’s EpiPen over a period of 8 years is the most recent outcry regarding expensive drug prices, Peter A. Ubel, MD, of Duke University and Peter B. Bach, MD, of Memorial Sloan Kettering Cancer Center, wrote in their commentary.
Ocular Therapeutix announced the enrollment of the first patient in the first of two planned phase 3 clinical trials with OTX-TP for the treatment of glaucoma and ocular hypertension. OTX-TP, which is placed in the canaliculus, is designed to deliver t…
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Open-Angle Glaucoma – Pipeline Review, H2 2016” report to their offering. Open-Angle Glaucoma pipeline therapeutics constitutes close to 38 molecules. Out of which approxi…